sfondo pallini







Developing and commercializing specialized therapies for the treatment of rare diseases by using the patient’s own blood

Latest News

View all

EryDel Provides Regulatory Update on EryDex for the Treatment of Ataxia ...

February 22, 2023

Read more

EryDel to Present its Phase 3 Study Results for Ataxia Telangiectasia ...

April 05, 2022

Read more
img ufficio

Our Technology

EryDel’s proprietary platform technology is an easy to use, fast and automatic bedside procedure, to encapsulate small and large molecules including therapeutic enzymes in patients’ red blood cells. The cells are immediately re-infused into patients providing prolonged half-life in circulation, reduced immunogenicity, better tolerability and predictable vascular distribution.


A late Stage
and Broad Pipeline

Our People

About us
luca-benatti +

Luca Benatti
Chief Executive Officer

giovanni-mambrini +

Giovanni Mambrini
Chief Operating Officer

thomas-sabia +

Thomas Sabia
Chief Commercial Officer

guenter-r-janhofer +

Guenter R. Janhofer
Chief Medical Officer